ABL Diagnostics wins court approval to buy TEXCELL operations

ABL Diagnostics has been selected by the Évry Commercial Court to acquire TEXCELL’s assets and business operations, a move that keeps the Genopole site in Évry-Courcouronnes open and transfers 29 employees. The deal expands ABL Diagnostics in virology, biosafety and infectious-disease services while adding an estimated €2.9 million in economic commitments financed from the group’s resources.

Why it matters: - The acquisition gives ABL Diagnostics a larger foothold in virology, biosafety and infectious-disease services. - The deal preserves scientific know-how and operations at the Genopole site in Évry-Courcouronnes. - ABL Diagnostics is adding complementary capabilities that can support its molecular diagnostics, healthcare software and clinical sample management businesses. - The transaction also brings in a recognized brand with international scientific credibility in biopharmaceutical testing and biological control.

What happened: - The Évry Commercial Court selected ABL Diagnostics to acquire TEXCELL’s assets and business operations. - ABL Diagnostics submitted an industrial plan focused on business continuity, preserving scientific expertise and building synergies with its existing activities. - The acquisition covers TEXCELL’s strategic assets and operations, plus commercial contracts transferred in the sale process. - The company plans to maintain operations at the Genopole site in Évry-Courcouronnes. - The deal transfers 29 employees, including 23 permanent staff and 6 apprentices or trainees. - ABL Diagnostics will also take on accrued employee rights tied to the transferred staff, valued at €91,829.24, subject to final adjustment.

The details: - TEXCELL emerged from the scientific ecosystem of the Institut Pasteur and has expertise in viral safety, biosafety, genomic analysis, immunological monitoring and services for biotechnology and innovative therapies. - Publicly available information puts TEXCELL France revenue at about €5.4 million in 2024, after €6.2 million in 2023 and €7.5 million in 2022. - The overall economic value of the project is estimated at about €2.9 million. - The purchase price for TEXCELL’s assets is €225,000, including €165,000 for intangible assets and €60,000 for tangible assets. - ABL Diagnostics will buy inventories for a lump-sum €30,000 excluding VAT. - The company will reconstitute security deposits of about €100,000. - The deal includes lease-financing agreements on operational equipment, with future lease payments of €531,792.74, subject to final adjustment. - ABL Diagnostics plans an industrial and technological investment program estimated at €930,000. - The company expects to add €1 million in working capital needs to support the acquired activities. - ABL Diagnostics said the transaction will be financed from the group’s available financial resources. - The accepted offer’s terms are in documents filed with the Évry Commercial Court. - TEXCELL’s expertise in viral safety, biological control, cell culture, viral characterization and biosafety complements ABL Diagnostics’ UltraGene, DeepChek® and Nadis® platforms. - The acquisition gives ABL Diagnostics an operational presence at Genopole Évry-Courcouronnes. - The company plans to recruit about five more employees to support scientific activities from TEXCELL. - ABL Diagnostics plans to continue developing characterized virus banks, cell line collections, virology expertise and biosafety infrastructure for future tools in biomedical research, biological quality control and molecular diagnostics. - ABL Diagnostics said the deal follows recent strategic initiatives with Institut Pasteur in Paris, including the HPV RNA-Seq genotyping project.

Between the lines: - The deal looks designed as both a rescue and a strategic bolt-on, preserving jobs and site continuity while buying specialized assets at a relatively small headline purchase price. - The emphasis on Institut Pasteur ties suggests ABL Diagnostics is building a broader science network around virology and infectious diseases rather than just expanding revenue. - The planned investment in automation, infrastructure and staff points to an integration phase that could turn TEXCELL’s legacy operations into a more scalable platform.

What’s next: - ABL Diagnostics said it will provide more information after the required legal and administrative formalities are completed. - The company expects to explain how the acquired activities will fit into its strategic roadmap and fiscal 2026 objectives. - Management plans further updates on integration, site development and hiring as the transaction moves forward.

The bottom line: - ABL Diagnostics is using the TEXCELL acquisition to deepen its position in virology and biosafety while keeping a scientific center and most of its workforce in place.